Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers

Archive ouverte

Bredel, Delphine | Tihic, Edi | Mouraud, Séverine | Danlos, François-Xavier | Susini, Sandrine | Aglave, Marine | Alfaro, Alexia | Mohamed-Djalim, Chifaou | Rouanne, Mathieu | Halse, Héloise | Bigorgne, Amélie | Tselikas, Lambros | Dalle, Stéphane | Hartl, Dana, M | Baudin, Eric | Guettier, Catherine | Vibert, Eric | Rosmorduc, Olivier | Robert, Caroline | Ferlicot, Sophie | Parier, Bastien | Albiges, Laurence | Mercier, Olaf | de Montpreville, Vincent, Thomas | Besse, Benjamin | Even, Caroline | Breuskin, Ingrid | Classe, Marion | Radulescu, Camélia | Lebret, Thierry | Pautier, Patricia | Gouy, Sébastien | Scoazec, Jean-Yves | Zitvogel, Laurence | Marabelle, Aurélien | Bonvalet, Mélodie

Edité par CCSD ; BioMed Central -

International audience. Background In addition to anti-PD(L)1, anti-CTLA-4 and anti-LAG-3, novel immune checkpoint proteins (ICP)-targeted antibodies have recently failed to demonstrate significant efficacy in clinical trials. In these trials, patients were enrolled without screening for drug target expression. Although these novel ICP-targeted antibodies were expected to stimulate anti-tumor CD8 + T-cells, the rationale for their target expression in human tumors relied on pre-clinical IHC stainings and transcriptomic data, which are poorly sensitive and specific techniques for assessing membrane protein expression on immune cell subsets. Our aim was to describe ICP expression on intratumoral T-cells from primary solid tumors to better design upcoming neoadjuvant cancer immunotherapy trials. Methods We prospectively performed multiparameter flow cytometry and single-cell RNA sequencing (scRNA-Seq) paired with TCR sequencing on freshly resected human primary tumors of various histological types to precisely determine ICP expression levels within T-cell subsets. Results Within a given tumor type, we found high inter-individual variability for tumor infiltrating CD45 + cells and for T-cells subsets. The proportions of CD8 + T-cells (~ 40%), CD4 + FoxP3-T-cells (~ 40%) and CD4 + FoxP3 + T-cells (~ 10%) were consistent across patients and indications. Intriguingly, both stimulatory (CD25, CD28, 4-1BB, ICOS, OX40) and inhibitory (PD-1, CTLA-4, PD-L1, CD39 and TIGIT) checkpoint proteins were predominantly co-expressed by intratumoral CD4 + FoxP3 + T-cells. ScRNA-Seq paired with TCR sequencing revealed that T-cells with high clonality and high ICP expressions comprised over 80% of FoxP3 + cells among CD4 + T-cells. Unsupervised clustering of flow cytometry and scRNAseq data identified subsets of CD8 + T-cells and of CD4 + FoxP3-T-cells expressing certain † Delphine Bredel and Edi Tihic contributed equally to this work.

Suggestions

Du même auteur

Immunodynamics of explanted human tumors for immuno-oncology

Archive ouverte | Dubuisson, Agathe | CCSD

International audience. Decision making in immuno-oncology is pivotal to adapt therapy to the tumor microenvironment (TME) of the patient among the numerous options of monoclonal antibodies or small molecules. Predi...

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

Archive ouverte | Rouanne, Mathieu | CCSD

International audience. Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mec...

Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma

Archive ouverte | Danlos, Francois-Xavier | CCSD

International audience. Unlabelled - Cancer immunotherapy combinations have recently been shown to improve the overall survival of advanced mesotheliomas, especially for patients responding to those treatments. We a...

Chargement des enrichissements...